A Phase 2 Open-label, Dose Escalation Study of HST5040 in Subjects With Propionic or Methylmalonic Acidemia Followed by a Randomized, Double-blind, Placebo-controlled, 2-period Crossover Study and an Open-label, Long-term Extension Study
Latest Information Update: 09 Jan 2024
At a glance
- Drugs HST 5040 (Primary)
- Indications Methylmalonic acidaemia; Propionic acidaemia
- Focus Therapeutic Use
- Acronyms HERO
- Sponsors HemoShear Therapeutics
Most Recent Events
- 03 Jan 2024 Status changed from recruiting to discontinued.
- 27 Sep 2023 Planned primary completion date changed from 31 Mar 2023 to 30 Mar 2024.
- 23 Feb 2023 Planned primary completion date changed from 31 Jan 2023 to 31 Mar 2023.